TVAX Biomedical is pioneering a novel cancer treatment approach known as TVAX Immunotherapy®, which combines personalized cancer cell vaccination with activated killer T cell therapy. This innovative platform is designed to enhance clinical outcomes for patients across various cancer types while maintaining low toxicity levels. The process begins with the surgical removal of cancer tissue, which is then converted into a personalized vaccine containing inactivated cancer cells. This vaccine is administered to the patient to stimulate the immune system, generating neoantigen-specific T cells that are crucial for targeting cancer cells.

Following vaccination, the partially activated T cells are collected from the patient's blood and further activated in a controlled manufacturing environment. These fully activated killer T cells are then reintroduced into the patient's body, where they specifically target and destroy cancer cells while sparing normal cells, thus minimizing side effects. TVAX Biomedical's lead product candidate, TVI-Brain-1, is currently under evaluation for treating glioblastoma and has received Fast Track Designation from the FDA, highlighting the potential of this immunotherapy platform to revolutionize cancer treatment.

United States

TVAX Biomedical is a biotechnology company currently performing phase 2b/3 clinical trials to test a unique cancer immunotherapy as a treatment for pediatric brain cancer.

TVAX Biomedical

Company Details